Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy. 2007

Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
Division of Nephrology, Saitama Children's Medical Center, 2100 Magome, Iwatsuki-ku, Saitama-city Saitama, 339 8551, Japan. f_shuich@d2.dion.ne.jp

Although diffuse crescentic formation in immunoglobulin A (IgA) nephropathy, histologically characterized by extensive extracapillary proliferation, is assumed to have a poor prognosis, there has still been no established treatment because of the low prevalence of the condition, especially in pediatric patients. This paper reports on a 5-year-old boy with rapidly progressive IgA nephropathy requiring dialysis for 1 month. He had been treated with plasma exchange (PE) combined with immunosuppressive treatment, including steroids and mizoribine, because renal function deteriorated rapidly despite initial treatment with intravenous methylprednisolone pulse. The histological findings at that time revealed IgA nephropathy, with large circumferential cellular crescent formation in approximately 80% of the glomeruli. Three weeks after PE initiation, serum levels of creatinine and IgA-containing immune complexes returned to normal, and urinary protein excretion gradually decreased. The second renal biopsy taken 7 months later demonstrated mild IgA nephropathy with small fibrocellular crescents. This case report indicates that PE combined with immunosuppressive treatment may benefit children with rapidly progressive IgA nephropathy, even when extensive crescent formations are present.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
January 1990, Journal of clinical apheresis,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
January 1995, Contributions to nephrology,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
July 1985, The International journal of artificial organs,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
March 2005, Indian journal of pediatrics,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
March 2005, Indian journal of pediatrics,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
July 1988, American journal of diseases of children (1960),
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
July 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
January 2007, Contributions to nephrology,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
June 1996, Transplantation proceedings,
Shuichiro Fujinaga, and Yoshiyuki Ohtomo, and Daisuke Umino, and Hiroshi Mochizuki, and Hitohiko Murakami, and Toshiaki Shimizu, and Yuichiro Yamashiro, and Kazunari Kaneko
January 1991, Nephron,
Copied contents to your clipboard!